WO1996000503B1 - Novel peptides - Google Patents
Novel peptidesInfo
- Publication number
- WO1996000503B1 WO1996000503B1 PCT/US1995/008156 US9508156W WO9600503B1 WO 1996000503 B1 WO1996000503 B1 WO 1996000503B1 US 9508156 W US9508156 W US 9508156W WO 9600503 B1 WO9600503 B1 WO 9600503B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- ser
- sequence
- amino acids
- oligopeptides
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000015636 Oligopeptides Human genes 0.000 claims abstract 6
- 108010038807 Oligopeptides Proteins 0.000 claims abstract 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims abstract 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims abstract 3
- 150000001413 amino acids Chemical class 0.000 claims 4
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 claims 2
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims 1
- 102100007628 SEMG1 Human genes 0.000 claims 1
- 101700085559 SEMG1 Proteins 0.000 claims 1
- 102100007622 SEMG2 Human genes 0.000 claims 1
- 101700003506 SEMG2 Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000004166 bioassay Methods 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
Abstract
Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.
Claims
1. An oligopeptide, not including Semenogelin I and II, that comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen.
2. The oligopeptide according to Claim 1 wherein the sequence of amino acids is
a) AsnLysIleSerTyrGln|Ser (SEQ.ID.NO.: 13),
b) LysIleSerTyrGln|Ser (SEQ.ID.NO.: 14),
c) GlyGluAsnGlyValGhjiysAspValSej<ϊlnXaaSerIleTyr|SerGlnThrGlu (SEQ.ID.NO.: 15) ,
d) GlyLysGlyIleSerSerGlnTyr|SerAsnThrGluGluArgLeu
(SEQ.ID.NO.: 2),
e) AsnLysIleSerTyrTyr|Ser (SEQ.ID.NO.: 127),
f) AsnLysAlaSerTyιGln|Ser (SEQ.ID.NO.: 128),
g) SerTyrGln|SerSer (SEQ.ID.NO.: 129);
h) LysTyrGlnlSerSer (SEQ.ID.NO.: 140); or
i) hArgTyrGln|SerSer (SEQ.ID.NO.: 141);
wherein hArg is homoarginine and Xaa is any natural amino acid.
3. The oligopeptide according to Claim 2 wherein the sequence of amino acids is
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SK1640-96A SK164096A3 (en) | 1994-06-28 | 1995-06-07 | Oligopeptide and a conjugate containing it |
RO96-02483A RO116198B1 (en) | 1994-06-28 | 1995-06-07 | Oligopeptide and conjugate thereof selectively cleaved by prostate specific antigen |
NZ290239A NZ290239A (en) | 1994-06-28 | 1995-06-07 | Peptides, oligopeptides with amino acid sequences that are recognised and proteolytically cleaved by free prostate specific antigen, assays and medicaments comprising such peptides |
EP95926602A EP0771209B1 (en) | 1994-06-28 | 1995-06-07 | Novel peptides |
DK95926602T DK0771209T3 (en) | 1994-06-28 | 1995-06-07 | New peptides |
AT95926602T ATE223224T1 (en) | 1994-06-28 | 1995-06-07 | NOVEL PEPTIDES |
DE69528064T DE69528064T2 (en) | 1994-06-28 | 1995-06-07 | NEW PEPTIDES |
HU9603564A HU220877B1 (en) | 1994-06-28 | 1995-06-07 | Novel olygopeptides, diagnostic methods for use thereof and conjugates for treatment of prostata cancer |
PL95317872A PL186341B1 (en) | 1994-06-28 | 1995-06-07 | Novel peptides |
AU30922/95A AU689934B2 (en) | 1994-06-28 | 1995-06-07 | Novel peptides |
BR9508151A BR9508151A (en) | 1994-06-28 | 1995-06-07 | Oligopeptide tests to determine the prostate-specific free antigen proteolytic activity in a sample and to identify compounds that inhibit prostate-specific antigen proteolytic activity and conjugate |
MX9700043A MX9700043A (en) | 1994-06-28 | 1995-06-07 | Novel peptides. |
JP8503422A JPH10502619A (en) | 1994-06-28 | 1995-06-07 | New peptide |
UA97010353A UA55371C2 (en) | 1994-06-28 | 1995-07-06 | Oligopeptides comprising amino acid sequences recognized and proteolytically cleaved by free prostate specific antigen, assay for protease activity of prostate specific antigen, method for identification of compounds inhibiting the proteolitical activity of said antigen, therapeutic agents comprising conjugates of such oligopeptides used for treatment of prostate cancer |
FI965225A FI965225A (en) | 1994-06-28 | 1996-12-27 | New peptides |
BG101077A BG63453B1 (en) | 1994-06-28 | 1996-12-27 | Peptides |
NO965592A NO965592L (en) | 1994-06-28 | 1996-12-27 | New peptides |
HK98109815A HK1009038A1 (en) | 1994-06-28 | 1998-08-11 | Novel peptides |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US267,092 | 1994-06-28 | ||
US08/267,092 US5599686A (en) | 1994-06-28 | 1994-06-28 | Peptides |
US40483395A | 1995-03-15 | 1995-03-15 | |
US404,833 | 1995-03-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996000503A1 WO1996000503A1 (en) | 1996-01-11 |
WO1996000503B1 true WO1996000503B1 (en) | 1996-02-22 |
Family
ID=26952210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/008156 WO1996000503A1 (en) | 1994-06-28 | 1995-06-07 | Novel peptides |
Country Status (27)
Country | Link |
---|---|
US (1) | US6143864A (en) |
EP (1) | EP0771209B1 (en) |
JP (1) | JPH10502619A (en) |
KR (1) | KR100379351B1 (en) |
CN (1) | CN1156964A (en) |
AT (1) | ATE223224T1 (en) |
AU (1) | AU689934B2 (en) |
BG (1) | BG63453B1 (en) |
BR (1) | BR9508151A (en) |
CA (1) | CA2192957A1 (en) |
CZ (1) | CZ381096A3 (en) |
DE (1) | DE69528064T2 (en) |
DK (1) | DK0771209T3 (en) |
ES (1) | ES2182908T3 (en) |
FI (1) | FI965225A (en) |
HK (1) | HK1009038A1 (en) |
HU (1) | HU220877B1 (en) |
MX (1) | MX9700043A (en) |
NO (1) | NO965592L (en) |
NZ (1) | NZ290239A (en) |
PL (1) | PL186341B1 (en) |
PT (1) | PT771209E (en) |
RO (1) | RO116198B1 (en) |
RU (1) | RU2162855C2 (en) |
SK (1) | SK164096A3 (en) |
UA (1) | UA55371C2 (en) |
WO (1) | WO1996000503A1 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5502037A (en) * | 1993-07-09 | 1996-03-26 | Neuromed Technologies, Inc. | Pro-cytotoxic drug conjugates for anticancer therapy |
US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
US5962216A (en) * | 1994-08-19 | 1999-10-05 | La Region Wallonne | Tumor-activated prodrug compounds and treatment |
JP2000506494A (en) * | 1995-10-18 | 2000-05-30 | メルク エンド カンパニー インコーポレーテッド | Complexes useful for treating benign prostatic hyperplasia |
US5952294A (en) * | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
US5998362A (en) * | 1996-09-12 | 1999-12-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6177404B1 (en) | 1996-10-15 | 2001-01-23 | Merck & Co., Inc. | Conjugates useful in the treatment of benign prostatic hyperplasia |
US5948750A (en) * | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
HRP970566A2 (en) * | 1996-10-30 | 1998-08-31 | Jones Deborah Defeo | Conjugates useful in the treatment of prostate canser |
EP0941334B1 (en) * | 1996-11-06 | 2004-06-02 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Protease-activatable pseudomonas exotoxin a-like proproteins |
US6545131B1 (en) | 1997-05-19 | 2003-04-08 | The Johns Hopkins University | Tissue specific prodrug |
AU7582298A (en) | 1997-05-19 | 1998-12-11 | Johns Hopkins University School Of Medicine, The | Tissue specific prodrug |
US6504014B1 (en) | 1997-05-19 | 2003-01-07 | The John Hopkins University | Tissue specific prodrug |
US6391305B1 (en) * | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
EP1036093A1 (en) * | 1997-12-02 | 2000-09-20 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
CA2321171A1 (en) * | 1998-03-05 | 1999-09-10 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6174858B1 (en) | 1998-11-17 | 2001-01-16 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
CA2368801A1 (en) * | 1999-04-30 | 2000-11-09 | Slil Biomedical Corporation | Conjugates as therapies for cancer and prostate diseases |
US6482943B1 (en) * | 1999-04-30 | 2002-11-19 | Slil Biomedical Corporation | Quinones as disease therapies |
US6649587B1 (en) | 1999-04-30 | 2003-11-18 | Slil Biomedical Corporation | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases |
WO2001025791A2 (en) * | 1999-10-07 | 2001-04-12 | Ciphergen Biosystems, Inc. | Prostate cancer marker proteins |
GB9924759D0 (en) | 1999-10-19 | 1999-12-22 | Merck Sharp & Dohme | Process for preparing peptide intermediates |
BR0109266A (en) | 2000-03-15 | 2003-04-29 | Bristol Myers Squibb Pharma Co | Compound, pharmaceutical composition, method of treating a cancer-affected mammal, method of releasing a compound into the cells of a cancer-affected mammal, and use of the compound |
EP1294404A2 (en) | 2000-06-14 | 2003-03-26 | Corixa Corporation | Prodrug compounds with an oligopeptide having an isoleucine residue |
EP1219634A1 (en) * | 2000-12-27 | 2002-07-03 | Bayer Aktiengesellschaft | Cytostatic-glycoconjugates having specifically cleavable peptidic linking units |
WO2002081630A2 (en) * | 2001-04-06 | 2002-10-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of semenogelin in the diagnosis, prognosis and treatment of cancer |
ES2388170T3 (en) * | 2001-08-24 | 2012-10-09 | Uvic Industry Partnerships Inc. | Proaerolysin containing protease activation sequences and methods of use for the treatment of prostate cancer |
IL162134A0 (en) * | 2001-11-28 | 2005-11-20 | Genset Sa | Human cDNAs and proteins, and uses thereof |
US7108976B2 (en) * | 2002-06-17 | 2006-09-19 | Affymetrix, Inc. | Complexity management of genomic DNA by locus specific amplification |
PL212929B1 (en) * | 2002-10-31 | 2012-12-31 | Metabasis Therapeutics Inc | Novel cytarabine monophosphate prodrugs |
WO2005041981A1 (en) * | 2003-10-31 | 2005-05-12 | Kurume University | Combination therapy of peptide vaccination and estramustine treatment |
DK1891093T3 (en) | 2005-06-14 | 2011-07-11 | Protox Therapeutics Inc | Method of treating or preventing benign prostate hyperplasia using modified pore-forming proteins |
JP5278873B2 (en) * | 2008-05-14 | 2013-09-04 | 国立大学法人九州工業大学 | Cancer diagnostic reagents |
US9046529B2 (en) | 2009-04-10 | 2015-06-02 | The Regents Of The University Of California | Prostatitis-associated antigens and methods of use thereof |
KR20110069618A (en) * | 2009-12-17 | 2011-06-23 | 주식회사 셀앤바이오 | Kit and method for diagnosis of prostate cancer |
US10449210B2 (en) | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
CN106687118A (en) | 2014-07-02 | 2017-05-17 | 配体药物公司 | Prodrug compounds and uses thereof |
AU2019207625A1 (en) | 2018-01-09 | 2020-07-30 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4296105A (en) * | 1978-08-03 | 1981-10-20 | Institut International De Pathologie Cellulaire Et Moleculaire | Derivatives of doxorubicine, their preparation and use |
US4277466A (en) * | 1978-08-29 | 1981-07-07 | Institut International De Pathologie Cellulaire Et Moleculaire | Complexes of DNA and esters derived from daunorubicine, their preparation and use |
US4446122A (en) * | 1979-12-28 | 1984-05-01 | Research Corporation | Purified human prostate antigen |
OA06421A (en) * | 1980-06-10 | 1981-09-30 | Omnium Chimique Sa | Process for the preparation of N- (vinblastinoyl-23) derivatives of amino acids and peptides. |
HUT34212A (en) * | 1983-04-29 | 1985-02-28 | Omnichem Sa | Process for the production of new vindblastin conjugates |
FR2546163B1 (en) * | 1983-05-16 | 1987-10-09 | Centre Nat Rech Scient | NOVEL HYDROSOLUBLE ACYLATED DERIVATIVES OF PEPTIDES OR AMINO ACIDS, THEIR PREPARATION AND THEIR APPLICATION |
EP0126344A2 (en) * | 1983-05-20 | 1984-11-28 | Abbott Laboratories | Tripeptide esters of therapeutic agents |
FR2583983B1 (en) * | 1985-06-07 | 1988-05-27 | Centre Nat Rech Scient | NOVEL WATER-SOLUBLE MACROMOLECULAR PRODUCTS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, ESPECIALLY ANTI-TUMOR AND PEST CONTROL |
EP0232693A3 (en) * | 1985-12-16 | 1988-04-06 | La Region Wallonne | Conjugates of vinblastine and its derivatives, process for their preparation and pharmaceutical compositions containing them |
FR2626882B1 (en) * | 1988-02-08 | 1991-11-08 | Ire Celltarg Sa | VINCA DERIVATIVE CONJUGATES COMPRISING A DETERGENT CHAIN IN POSITION C-3 |
US5391723A (en) * | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US5220001A (en) * | 1989-10-25 | 1993-06-15 | Zaidan Hojim Biseibutsu Dong-A Pharm Co. | Anthracycline glycoside derivatives |
US5137877B1 (en) * | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
SE9002480D0 (en) * | 1990-07-23 | 1990-07-23 | Hans Lilja | ASSAY OF FREE AND COMPLEXED PROSTATE-SPECIFIC ANTIGEN |
FR2678274A1 (en) * | 1991-06-25 | 1992-12-31 | Medgenix Group Sa | N-Leucylepirubicin, application as antitumour medicinal product and process for preparing it |
US5288612A (en) * | 1991-07-03 | 1994-02-22 | The Scripps Research Institute | Assay methods for detecting serum proteases, particularly activated protein C |
US5622929A (en) * | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
DE4233152A1 (en) * | 1992-10-02 | 1994-04-07 | Behringwerke Ag | Antibody-enzyme conjugates for prodrug activation |
EP0667920B1 (en) * | 1992-10-29 | 2003-01-15 | Thomas Jefferson University | Methods of detecting micrometastasis of prostate cancer |
AU6364094A (en) * | 1993-03-12 | 1994-09-26 | Board Of Regents, The University Of Texas System | Anthracyclines with unusually high activity against cells resistant to doxorubicin and its analogs |
WO1995030758A1 (en) * | 1994-05-10 | 1995-11-16 | Mayo Foundation For Medical Education And Research | Recombinant hk2 polypeptide |
US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
US5599686A (en) * | 1994-06-28 | 1997-02-04 | Merck & Co., Inc. | Peptides |
US5962216A (en) * | 1994-08-19 | 1999-10-05 | La Region Wallonne | Tumor-activated prodrug compounds and treatment |
AUPM769394A0 (en) * | 1994-08-25 | 1994-09-15 | Commonwealth Scientific And Industrial Research Organisation | Assay for the detection of proteases |
-
1995
- 1995-06-06 US US08/468,161 patent/US6143864A/en not_active Expired - Fee Related
- 1995-06-07 RO RO96-02483A patent/RO116198B1/en unknown
- 1995-06-07 JP JP8503422A patent/JPH10502619A/en active Pending
- 1995-06-07 AT AT95926602T patent/ATE223224T1/en not_active IP Right Cessation
- 1995-06-07 WO PCT/US1995/008156 patent/WO1996000503A1/en not_active Application Discontinuation
- 1995-06-07 CN CN95194855A patent/CN1156964A/en active Pending
- 1995-06-07 MX MX9700043A patent/MX9700043A/en active IP Right Grant
- 1995-06-07 CA CA002192957A patent/CA2192957A1/en not_active Abandoned
- 1995-06-07 AU AU30922/95A patent/AU689934B2/en not_active Revoked
- 1995-06-07 PL PL95317872A patent/PL186341B1/en not_active IP Right Cessation
- 1995-06-07 BR BR9508151A patent/BR9508151A/en not_active IP Right Cessation
- 1995-06-07 HU HU9603564A patent/HU220877B1/en not_active IP Right Cessation
- 1995-06-07 CZ CZ963810A patent/CZ381096A3/en unknown
- 1995-06-07 ES ES95926602T patent/ES2182908T3/en not_active Expired - Lifetime
- 1995-06-07 SK SK1640-96A patent/SK164096A3/en unknown
- 1995-06-07 DK DK95926602T patent/DK0771209T3/en active
- 1995-06-07 PT PT95926602T patent/PT771209E/en unknown
- 1995-06-07 NZ NZ290239A patent/NZ290239A/en not_active IP Right Cessation
- 1995-06-07 RU RU97101169/04A patent/RU2162855C2/en not_active IP Right Cessation
- 1995-06-07 EP EP95926602A patent/EP0771209B1/en not_active Expired - Lifetime
- 1995-06-07 DE DE69528064T patent/DE69528064T2/en not_active Expired - Fee Related
- 1995-06-07 KR KR1019960707514A patent/KR100379351B1/en not_active IP Right Cessation
- 1995-07-06 UA UA97010353A patent/UA55371C2/en unknown
-
1996
- 1996-12-27 BG BG101077A patent/BG63453B1/en unknown
- 1996-12-27 NO NO965592A patent/NO965592L/en unknown
- 1996-12-27 FI FI965225A patent/FI965225A/en unknown
-
1998
- 1998-08-11 HK HK98109815A patent/HK1009038A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996000503B1 (en) | Novel peptides | |
HU9603564D0 (en) | Novel peptides | |
EP0591524A4 (en) | ||
IL128829A0 (en) | Improved solid-phase peptide and agent for use in such synthesis | |
CA2050336A1 (en) | Yeast processing system comprising a negatively charged amino acid adjacent to the processing site | |
WO1997028247A3 (en) | AMINO ACID-ENRICHED PLANT PROTEIN RESERVES, PARTICULARLY LYSINE-ENRICHED MAIZE η-ZEIN, AND PLANTS EXPRESSING SUCH PROTEINS | |
EP1623994A3 (en) | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components | |
AU5222498A (en) | Type i recombinant clostridium histolyticum collagenase and its use for isolating cells and cell aggregates | |
DK0531404T3 (en) | Ubiquitin-specific protease | |
AU1353295A (en) | Peptides derived from a retrovirus of the HIV group, and their use | |
AU1003888A (en) | Pancreatic secretory trypsin inhibitor and variants thereof produced by a recombinant host, process, expression vector and recombinant host therefore and pharmaceutical use thereof | |
De Camargo et al. | Influence of the carboxyl terminus of luteinizing hormone-releasing hormone and bradykinin on hydrolysis by brain endo-oligopeptidases. | |
EP0528686B8 (en) | Process for producing peptides | |
AU6710998A (en) | Process for preparing modified proteins | |
AU3850997A (en) | Immunologically active proteins of borrelia burgdorferi, coded nuclein acids of such and their use in test kits and vaccines | |
Yonezawa et al. | Substrate specificity of cucumisin on synthetic peptides | |
Bányai et al. | Proximity of the catalytic region and the kringle 2 domain in the closed conformer of plasminogen | |
Levy et al. | The digestion of the oxidized B chain of insulin by human neutrophile proteases: elastase and chymotrypsin-like protease | |
ATE283914T1 (en) | IGA1 PROTEASE FRAGMENT AS A CARRIER PEPTIDE | |
Uddin et al. | Specific cleavage of synthetic renin substrate by mouse γ-nerve growth factor | |
TR199701538T1 (en) | Nucleic acid and amino acid sequences of Helibacter pylorus. |